Daniel A Heinrich1, Claudia Reinholz2, Maximilian Bauer3, Amanda Tufman3,4, Richard Frohner2, Jochen Schopohl2, Martin Bidlingmaier2, Robert P Kosilek2, Martin Reincke2, Harald J Schneider2. 1. Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ziemssenstraße 1, 80331, München, Germany. daniel.heinrich@med.uni-muenchen.de. 2. Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ziemssenstraße 1, 80331, München, Germany. 3. Asklepios Fachkliniken München-Gauting, Lehrklinik der LMU München, Robert-Koch-Allee 2, 82131, Gauting, Germany. 4. Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Ziemssenstraße 1, 80331, München, Germany.
Abstract
PURPOSE: Recent epidemiologic studies suggest a high prevalence of acromegaly. The prevalence of obstructive sleep apnea syndrome (OSAS) in acromegaly patients ranges from 47 to 70%. A recent study identified 2 patients with acromegaly among 567 OSAS patients. However, it remains unclear whether screening for acromegaly among OSAS patients is necessary. The aim was to screen for acromegaly among OSAS patients by measuring IGF-1 levels and performing confirmatory tests if necessary. METHODS: We performed a prospective cross-sectional diagnostic study on the prevalence of acromegaly in patients with OSAS. A total of 507 patients with a confirmed diagnosis of OSAS (357 male, 150 female) were screened. RESULTS: Seven male and three female patients (1.97% of total) were positively screened for elevated IGF-1 levels. Nine out of ten patients suppressed growth hormone levels during OGTT excluding acromegaly, whereas one individual was identified to have acromegaly according to established criteria (1/507, prevalence 0.2%). Analysis of the data showed no correlation between elevated IGF-1 values and the severity of OSAS or BMI. CONCLUSIONS: Our data demonstrate a low prevalence of acromegaly in patients with OSAS. Until data from population-based studies is available we suggest restricting screening for acromegaly in OSAS to those patients who have additional clinical features of acromegaly.
PURPOSE: Recent epidemiologic studies suggest a high prevalence of acromegaly. The prevalence of obstructive sleep apnea syndrome (OSAS) in acromegalypatients ranges from 47 to 70%. A recent study identified 2 patients with acromegaly among 567 OSAS patients. However, it remains unclear whether screening for acromegaly among OSAS patients is necessary. The aim was to screen for acromegaly among OSAS patients by measuring IGF-1 levels and performing confirmatory tests if necessary. METHODS: We performed a prospective cross-sectional diagnostic study on the prevalence of acromegaly in patients with OSAS. A total of 507 patients with a confirmed diagnosis of OSAS (357 male, 150 female) were screened. RESULTS: Seven male and three female patients (1.97% of total) were positively screened for elevated IGF-1 levels. Nine out of ten patients suppressed growth hormone levels during OGTT excluding acromegaly, whereas one individual was identified to have acromegaly according to established criteria (1/507, prevalence 0.2%). Analysis of the data showed no correlation between elevated IGF-1 values and the severity of OSAS or BMI. CONCLUSIONS: Our data demonstrate a low prevalence of acromegaly in patients with OSAS. Until data from population-based studies is available we suggest restricting screening for acromegaly in OSAS to those patients who have additional clinical features of acromegaly.
Authors: J Roemmler; B Gutt; R Fischer; S Vay; A Wiesmeth; M Bidlingmaier; J Schopohl; M Angstwurm Journal: Sleep Breath Date: 2012-01-13 Impact factor: 2.816
Authors: Patrick Petrossians; Adrian F Daly; Emil Natchev; Luigi Maione; Karin Blijdorp; Mona Sahnoun-Fathallah; Renata Auriemma; Alpha M Diallo; Anna-Lena Hulting; Diego Ferone; Vaclav Hana; Silvia Filipponi; Caroline Sievers; Claudia Nogueira; Carmen Fajardo-Montañana; Davide Carvalho; Vaclav Hana; Günter K Stalla; Marie-Lise Jaffrain-Réa; Brigitte Delemer; Annamaria Colao; Thierry Brue; Sebastian J C M M Neggers; Sabina Zacharieva; Philippe Chanson; Albert Beckers Journal: Endocr Relat Cancer Date: 2017-07-21 Impact factor: 5.678
Authors: Konstantina Vouzouneraki; Karl A Franklin; Maria Forsgren; Maria Wärn; Jenny Tiberg Persson; Helena Wik; Christina Dahlgren; Ann-Sofie Nilsson; Caroline Alkebro; Pia Burman; Eva-Marie Erfurth; Jeanette Wahlberg; Anna-Karin Åkerman; Charlotte Høybye; Oskar Ragnarsson; Britt Edén Engström; Per Dahlqvist Journal: Endocrine Date: 2018-07-31 Impact factor: 3.633